Compare NGVT & KLRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NGVT | KLRA |
|---|---|---|
| Founded | 1964 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.4B |
| IPO Year | 2015 | 2026 |
| Metric | NGVT | KLRA |
|---|---|---|
| Price | $71.47 | $12.89 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $72.50 | N/A |
| AVG Volume (30 Days) | 186.6K | ★ 780.3K |
| Earning Date | 05-06-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.10 | N/A |
| EPS | ★ 2.67 | N/A |
| Revenue | ★ $1,167,600,000.00 | N/A |
| Revenue This Year | $3.63 | N/A |
| Revenue Next Year | $0.50 | N/A |
| P/E Ratio | $25.83 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $45.85 | $11.84 |
| 52 Week High | $79.29 | $23.82 |
| Indicator | NGVT | KLRA |
|---|---|---|
| Relative Strength Index (RSI) | 51.39 | 30.66 |
| Support Level | $68.24 | N/A |
| Resistance Level | $70.69 | $19.15 |
| Average True Range (ATR) | 1.81 | 0.97 |
| MACD | 0.27 | -0.23 |
| Stochastic Oscillator | 75.90 | 12.45 |
Ingevity Corp is a chemical manufacturer based in the United States. It conducts its operations through three segments, namely Performance Chemicals, Advanced Polymer Technologies, and Performance Materials. The bulk of its revenue is generated by the Performance Chemicals segment which deals with the manufacture and sale of specialty chemicals that find their use in a range of processes such as asphalt paving, oil exploration and production, agrochemicals, adhesives, lubricants, and publication inks. The Performance Materials segment, on the other hand, focuses on automotive carbon products used in automobiles. The Advanced Polymer Technologies segment produces caprolactone and caprolactone-based specialty polymers. The company generates the majority of its revenue from North America.
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.